BioCardia Full Year 2023 Earnings: Misses Expectations






BioCardia (NASDAQ:BCDA) Full Year 2023 Results

Key Financial Results

  • Revenue: US$477.0k (down 65% from FY 2022).
  • Net loss: US$11.6m (loss narrowed by 2.8% from FY 2022).
  • US$0.55 loss per share (improved from US$0.67 loss in FY 2022).
NasdaqCM:BCDA Earnings and Revenue History March 29th 2024

All figures shown in the chart above are for the trailing 12 month (TTM) period

BioCardia Revenues and Earnings Miss Expectations

Revenue missed analyst estimates by 32%. Earnings per share (EPS) also missed analyst estimates by 20%.

Looking ahead, revenue is forecast to grow 69% p.a. on average during the next 3 years, compared to a 18% growth forecast for the Biotechs industry in the US.

Performance of the American Biotechs industry.

The company's shares are up 1.8% from a week ago.

Risk Analysis

You still need to take note of risks, for example - BioCardia has 8 warning signs (and 3 which are a bit concerning) we think you should know about.

Every question you ask will be answered
Scan the QR code to contact us
Also you can contact us via